MOSES serves as both compass and crucible, guiding researchers through chemical space while rigorously testing their innovations.
The rise of biocatalysis and flow chemistry demands periodic updates to fragment libraries and complexity metrics.
AI algorithms now design molecules from scratch, optimizing pharmacological profiles through iterative learning.
AI-driven de novo protein design is transforming the way scientists approach molecular engineering.
Polaritonic chemistry steers, inhibits, and catalyzes chemical processes at room temperature, controlled by parameters like cavity mirror spacing.
The encapsulation of norfloxacin in PEBSA-based microparticles marks a transformative development in antibiotic delivery.
Targeting osteopontin could redefine the landscape of cancer therapy, transforming resistance into a treatable challenge.
Histidine-lysine (HK) peptides could transform siRNA therapeutics, enabling personalized cancer care and tackling untreatable conditions.
By targeting ferroptosis, apoptosis, and autophagy while modulating MYC, TG1 disrupts the intricate survival networks of CRC cells.
Despite advances, key gaps in understanding insulin resistance persist, including CNS diagnostics, brain-periphery interactions, and apoE isoform roles, highlighting critical research priorities for new treatments.
As medicine moves toward precision approaches, the role of glucocorticoids in trauma care warrants careful reconsideration.
In the era of precision medicine, the golden age of nanotechnology is just beginning.
As our understanding of AUD’s genetic and molecular landscape deepens, so does the potential for innovative treatments that go beyond traditional approaches.
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settings
